Notícias e Atividades da Castle Biosciences
Presença
Castle Biosciences é uma das ...
Castle Biosciences é uma empresa listada sob o símbolo CSTL (US).
Executivos
Veja o organograma con seus 28 executivos principais
Biografias mais buscadas da Castle Biosciences
- Derek Maetzold, Director, President and Chief Executive Officer
- Tiffany Olson, Director
- Miles Harrison, Director
Criar um alerta
para seguir os movimentos de executivos da Castle Biosciences.
Biotecnologia
Castle Biosciences possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).
Popular M&A news in Biotecnologia
- Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
- BioNTech has announced the acquisition of CureVac (publicado em 12 de junho de 2025).
- SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Castle Biosciences
- Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
- Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
- New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
- Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
- Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
- Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
- Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
- Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
- Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
- Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
- View more press releases Close
Redes sociais sobre Castle Biosciences
- Castle Biosciences na Wikipedia, Google News e Yahoo Finance
- Castle Biosciences na LinkedIn, Twitter e YouTube
